EYPT SHAREHOLDER ALERT: EyePoint Pharmaceuticals Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of EyePoint Pharmaceuticals (“EyePoint” or the “Company”) (NASDAQ: EYPT) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.

[LEARN MORE ABOUT THE INVESTIGATION]

What Happened?

On August 14, 2026, EyePoint released topline results in its Phase 3 LUGANO wet AMD trial for DURAVYU, revealing that DURAVYU missed the prespecified primary endpoint—change in best-corrected visual acuity versus on-label aflibercept. Previously, on March 25, 2026, President and CEO Jay S. Duker had stated they were “highly confident in the results of these trials [including Phase 3 LUGANO] at this point for a lot of reasons.” On June 9, he reiterated that they “remain quite confident and quite optimistic in the results and we think we can make a difference for patients.” On this news, the Company’s stock price declined $9.88, or 67%, to close at $4.87 on August 17, 2026.

What Should I Do?

At this stage, no lawsuit has been filed. The investigation is ongoing to determine whether claims may be brought under federal securities laws.

If you purchased or otherwise acquired EyePoint securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at [e-mail], or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.

[LEARN MORE ABOUT SECURITIES CLASS ACTIONS]

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.